deoxymycetin methyl ester (DZ2002) / Ningbo Ziyuan Pharmaceutical, Shanghai Inst. of Materia Medica - LARVOL DELTA

Role of DZ2002 in reducing corneal graft rejection in rats by influencing Th17 activation via inhibition of the PI3K/AKT pathway and downregulation of TRAF1. (PubMed, Open Life Sci) - "The effect of DZ2002 in alleviating rejection was attributed to the downregulation of TRAF1 expression, inhibition of the PI3K/AKT pathway, decreased expression of chemokine CCL5 in the aqueous humor, and suppression of the differentiation of T cells into Th17 cells. DZ2002 was effective in reducing corneal graft rejection in rats by downregulating TRAF1 and modulating Th17 differentiation."

Journal • Preclinical • Ophthalmology • Transplant Rejection • Transplantation • TRAF1

S-Adenosylhomocysteine hydrolase inhibitor DZ2002 promotes diabetic wound healing by regulating Macrophage-Mediated inflammation through the mixed lineage leukemia 1-H3K4me3 axis. (PubMed, Biochem Pharmacol) - "Collectively, our findings demonstrate that DZ2002 effectively promotes diabetic wound healing by targeting the MLL1/H3K4me3 axis to resolve sustained macrophage inflammation. Moreover, this work validates SAHH as a critical upstream regulator of this pathogenic epigenetic pathway, offering a novel therapeutic strategy for chronic diabetic wounds."

Journal • CNS Disorders • Dermatology • Diabetes • Dry Eye Disease • Hematological Malignancies • Immunology • Leukemia • Metabolic Disorders • Multiple Sclerosis • Oncology • Ophthalmology • Psoriasis • Scleroderma • Systemic Sclerosis